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Abstract: Of the major components of the kynurenine pathway for the oxidative metabolism of tryptophan, most attention has focussed 
on the N-methyl-D-aspartate (NMDA) receptor agonist quinolinic acid, and the glutamate receptor blocker kynurenic acid. However, 
there is increasing evidence that the redox-active compound 3-hydroxyanthranilic acid may also have potent actions on cell function 
in the nervous and immune systems, and recent clinical data show marked changes in the levels of this compound, associated with 
changes in anthranilic acid levels, in patients with a range of neurological and other disorders including osteoporosis, chronic brain 
injury, Huntington’s disease, coronary heart disease, thoracic disease, stroke and depression. In most cases, there is a decrease in 
3-hydroxyanthranilic acid levels and an increase in anthranilic acid levels. In this paper, we summarise the range of data obtained to 
date, and hypothesise that the levels of 3-hydroxyanthranilic acid or the ratio of 3-hydroxyanthranilic acid to anthranilic acid levels, 
may contribute to disorders with an inflammatory component, and may represent a novel marker for the assessment of inflammation and 
its progression. Data are presented which suggest that the ratio between these two compounds is not a simple determinant of neuronal 
viability. Finally, a hypothesis is presented to account for the development of the observed changes in 3-hydroxyanthranilic acid and 
anthranilate levels in inflammation and it is suggested that the change of the 3HAA:AA ratio, particularly in the brain, could possibly 
be a protective response to limit primary and secondary damage.
Keywords: anthranilic acid, 3-hydroxyanthranilic acid, inflammation, Huntington’s disease, stroke; kynureninesDarlington et al
52  International Journal of Tryptophan Research 2010:3
Introduction
In many organs and tissues, the major route for the 
metabolism of tryptophan is the kynurenine pathway. 
The initial enzymes for this pathway are indoleamine-
2.3-dioxygenase (IDO), present in most organs and tis-
sues except the liver, and tryptophan-2,3-dioxygenase 
(TDO). The latter is present almost exclusively in the 
liver, although low levels—usually associated with 
the presence of specific cell types such as leucocytes 
or endothelial cells—have been demonstrated in areas 
such as the CNS.1–3 This includes the demonstration 
using immunohistochemistry, of TDO occurrence in 
neurons.1
Although recognised for many years as an impor-
tant route for the endogenous synthesis of nicotinic 
acid  and,  thus,  of  the  vital  co-factor  nicotinamide 
adenine  dinucleotide  (NAD),  it  was  only  in  1981 
that specific actions on cellular receptors were dis-
covered, with the demonstration that quinolinic acid 
was an agonist at receptors for the neurotransmitter 
glutamate, specifically those sensitive to N-methyl-
D-aspartate (NMDA).4 A more extensive screening 
of the kynurenine pathway components then led to 
the discovery that kynurenic acid was an antagonist 
at glutamate receptors,5 with later work showing a 
preference for blocking NMDA receptors at the co-
agonist site for glycine (the glycineB or strychnine-
resistant glycine receptors).6
Since that early work, these two tryptophan metab-
olites have been implicated in a wide range of neu-
rological and psychiatric disorders,7–10 but it has also 
been recognised that other components of the kyn-
urenine pathway, notable 3-hydroxykynurenine and 
3-hydroxyanthranilic  acid  are  highly  redox-active, 
and might play a role in the regulation of oxidative 
stress.11,12 In this paper, a possible rationale for these 
latter compounds playing a significant role in disor-
ders with an inflammatory component will be pre-
sented, together with a hypothesis of how changes in 
their endogenous levels arise.
The 3-hydroxyanthranilic Acid: 
Anthranilic Acid Ratio
Human studies
osteoporosis
The  first  indication  that  3-hydroxyanthranilic  acid 
may  be  of  significance  in  a  disease  process  arose 
from a study of a peripheral disorder, osteoporosis. 
This disorder is most frequently observed in post-
menopausal women and elderly men, and has been 
claimed to have a substantial inflammatory compo-
nent. It is also a common consequence of treating 
patients with corticosteroid drugs.
In a series of 29 patients (compared with 10 con-
trol  subjects),  none  of  whom  was  consuming  ste-
roids at the time, blood samples were taken at the 
initial clinical presentation and formal diagnosis of 
osteoporosis, which included a Dual-Energy X-ray 
Absorptiometry  (DEXA)  scan  to  determine  bone 
density.  The  concentrations  in  the  plasma  of  the 
major components of the kynurenine pathway were 
subsequently measured by HPLC.13 Similar analyses 
were made of samples taken from the same patients 
after 2 years of standard pharmacological treatment 
with either the bisphosphonate drug etidronate, or 
the selective oestrogen receptor modulator (SERM) 
drug, raloxifene—currently accepted therapies at the 
time of this study.
One of the most striking changes noted was that 
at the time of diagnosis, those patients with osteo-
porosis  exhibited  much  lower  baseline  levels  of 
3-hydroxyanthranilic  acid  (1.04  ±  0.10  nM)  when 
compared  with  the  healthy  controls  i.e.  (7.89  ± 
1.15 nM). In contrast, the levels of anthranilic acid 
were substantially increased (139.2 ± 14.7 nM) com-
pared with controls (21.56 ± 2.25 nM) and the 3HAA:
AA ratio had reversed.
Following the 2 year period of therapy, a repeated 
DEXA scan confirmed significant improvements in 
bone density in those patients receiving etidronate. 
The  biochemical  analyses  revealed  that  the  levels 
of  3-hydroxyanthranilic  acid,  anthranilic  acid,  and 
the 3HAA:AA ratio were all comparable with con-
trol values. In addition, the levels of tryptophan itself 
had increased significantly when compared with the 
original, baseline values (see Table 1).
Huntington’s disease and brain injury patients
In parallel with this study, an analysis of the kyn-
urenine pathway was also undertaken in patients with 
severe Huntington’s disease,14 the patients being suffi-
ciently disabled that they were permanently hospital-
ised, and also in a group of patients with head injuries 
sustained at least one year before blood sampling.15 
In both groups of patients, i.e end stage Huntington’s 3-hydroxyanthranilic acid
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Table 1. Levels (mean ± s.e. mean) and ratios of 3-hydroxyanthranilic acid (3HAA) and anthranilic acid (AA) in control 
subjects and patients with various clinical conditions.
Medical condition 
 
Mean 3HAA  
level (patients)  
nmol/l
Mean 3HAA  
level (controls)  
nmol/l
Mean AA level  
(patients)  
nmol/l
Mean AA level  
(controls)  
nmol/l
Mean 3HAA: 
AA ratio 
(patients)
Mean 3HAA: 
AA ratio  
(controls)
stroke (baseline)
T: total (n = 50) T: 9.62 ± 1.22 23.74 ± 1.55 T: 54.66 ± 9.15 28.59 ± 1.63 T: 1:5.68 1:1.20
I: ischaemic  
(n = 36)
I: 10.4 ± 1.45 I: 55.2 ± 11.66 I: 1:5.31
H: haemorrhagic (9) H: 5.44 ± 2.17 H: 54.08 ± 6.15 H: 1:9.94
c: controls (n = 35)
stroke (14 days) T: 10.07 ± 1.32 T: 40.89 ± 8.32 T: 1:4.06 1:1.20
I: 10.18 ± 1.69 I: 35.05 ± 4.68 I: 1:3.44
H: 9.52 ± 2.78 H: 25.4 ± 4.92 H: 1:2.67
chronic brain 1.52 ± 0.26 7.71 ± 1.21 105.65 ± 8.8 72.85 ± 5.72 1:69.51 1:9.45
Injury (n = 15)
controls (n = 15)
Huntington’s 1.29 ± 0.77 7.71 ± 1.21 108.06 ± 21.77 72.85 ± 5.72 1:83.77 1:9.45
disease 1
HD (n = 11)
controls (n = 15)
Huntington’s
disease 2*
group o-ve (n = 29) 0–28.45 ± 1.88 26.26 ± 2.71 0–23.43 ± 1.78 23.06 ± 2.58 1:0.82 1:0.88
group o+ve (n = 19) 0 + 28.37 ± 3.06 0 + 20.94 ± 1.21 1:0.74
group 1+ (n = 14) 1 + 25.94 ± 2.73 1 + 21.94 ± 1.87 1:0.85
group 2+ (n = 40) 2 + 24.65 ± 1.8 2 + 23.42 ± 1.21 1:0.95
controls (n = 11)
coronary bypass  
(n = 28)
9.04 ± 0.91 33.25 ± 3.02 1:3.68
Thoracic surgery  
(n = 28)
6.28 ± 0.76 34.69 ± 2.74 1:5.54
Depression
ssRI (n = 19) 21.06 ± 1.64 23.20 ± 2.04 28.33 ± 4.8 24.64 ± 2.93 1:1.35
ssRI + T3 (n = 9) 24.98 ± 3.88 27.39 ± 3.88 1:1.10 (on  
drugs)
controls (n = 18) 1:1.06 (not on  
drugs)
Osteoporosis 1.04 ± 0.13 7.89 ± 1.15 139.2 ± 14.7 21.56 ± 2.25 1:134 1:2.73
patients (n = 29)
controls (n = 10)            
*Huntington’s disease 2.
Group o-ve = Gene −ve asymptomatic HD family member.
Group o+ve = Gene +ve, asymptomatic HD family member.
Group 1+ = Gene +ve mildly affected HD family member.
Group 2+ = Gene +ve severely affected HD family member.
References: stroke;17 brain injury;15 HD1;14 HD2;16 depression;18 osteoporosis.13Darlington et al
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disease and chronic brain injury patients, one of the 
most consistent and marked changes in the kynuren-
ine pathway proved to be in the pair of metabolites, 
3-hydroxyanthranilic acid and anthranilic acid, with 
the ratio between these being reversed with AA levels 
being higher than 3-hydroxyanthranilic acid levels, 
which contrasts with the 3HAA:AA ratio in healthy 
control subjects (Table 1).
In  another  study  of  Huntington’s  disease  (HD) 
patients16 (including HD gene negative and HD gene 
positive patients, the latter with mild, moderate or 
severe disease), there was no change in the 3HAA:
AA ratio, a finding which may attributable to the fact 
that many patients in this second study were at early 
stages of the disease progression. This would be con-
sistent with the finding in the same study of highly 
significant  correlations  between  tryptophan  levels 
in the blood and disease severity as indicated by the 
number of CAG motif repeats (negative correlation, 
p = 0.0004), and between the kynurenine:tryptophan 
ratio  and  CAG  repeat  length  (positive  correlation, 
p = 0.0025).16
In neither of these two patient groups is there any 
available pharmacological strategy for significantly 
improving the long-term outcome of the brain injury 
or neurodegeneration, so therapeutic studies to assess 
responses to drug therapies as performed in osteopo-
rosis patients (above) are not currently possible.
stroke
In a later study of stroke injury, a series of patients 
experiencing a stroke (or relatives of the patients) con-
sented to the taking of a series of blood samples dur-
ing hospitalisation. The results indicated not only that 
the kynurenine pathway had indeed been activated by 
the development or occurrence of the infarct, since the 
kynurenine:tryptophan  ratio  was  very  significantly 
raised, but also that the ratio of 3-hydroxyanthranilic 
acid to anthranilic acid was again decreased to about 
20% of control levels at 24 hours after the stroke, 
irrespective of whether the latter was ischaemic or 
haemorrhagic.17
Several  additional  features  of  the  3HAA:AA 
ratio  were  striking  in  these  patients.  Firstly,  the 
3HAA: AA ratio remained substantially lower than 
control subjects at 14 days after the stroke. Secondly, 
a subgroup analysis revealed that the most severely 
affected patients—those who died within 21 days of 
the stroke—exhibited values for the 3HAA:AA ratio 
which were significantly lower than those patients 
who survived beyond this time.17 It was also inter-
esting to see that patients who did not survive the 
stroke had significantly higher levels of kynurenic 
acid than those who did survive, a fact which tempts 
speculation about the potentially protective role of 
kynurenic  acid  in  acute  stroke  patients.17  Lastly, 
a  comparison  between  the  3HAA:AA  ratio  and 
the size of the cerebral infarct, estimated from CT 
scans, indicated consistent, statistically significant 
negative correlations between 3-hydroxyanthranilic 
acid levels and infarct size up to 7 days following 
the stroke, with Spearman correlation coefficients of 
–0.466 (P  0.05) at 24 hours, –0.433 (P  0.01) at 
48 hours, –0.359 (P  0.05) at 72 hours, and –0.478 
(P  0.05) at 7 days.
cardiac bypass or thoracic surgery
In a further clinical study, as yet unpublished, the 
3HAA:AA ratio was also reversed in two groups of 
patients,  those  about  to  undergo  coronary  by-pass 
grafting and those about to have surgery for other 
intrathoracic pathologies, frequently neoplastic.
Depression
Finally, in a clinical study of non-hospitalised patients 
suffering from depression the 3HAA:AA ratio was 
again reversed before drug treatment or counselling 
had begun.18
experimental study
In  order  to  determine  whether  the  ratio  between 
3-hydroxyanthranilic  acid  and  anthranilic  acid  had 
any  effects  on  neuronal  viability,  cerebellar  gran-
ule  neurons  were  cultured  from  neonatal  rats  and 
maintained in culture for 9 days as described previ-
ously19 before different concentrations and ratios of 
3-hydroxyanthranilic acid and anthranilic acid were 
added. These compounds were left in contact with the 
neurons for 5 hours, after which the viability of the 
neurons was examined using the Alamar Blue (Bio-
source) assay. The results are summarised in Figure 1, 
which indicates that, although there was a tendency 
for viability to decrease after exposure to higher con-
centrations of the two compounds, there was no over-
all evidence for a significant deleterious effect of any 
concentration, or combination of concentrations, on 3-hydroxyanthranilic acid
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viability. In particular, there was no indication that 
the combination of these two substances generated 
neuronal death at levels greater than either compound 
alone,  nor  was  there  any  indication  that  the  toxic 
effects of 3-hydroxyanthranilic acid which have been 
reported on some cell types20 were evident on cere-
bellar granule neurons and could be exacerbated or 
prevented by anthranilic acid.
Clearly these remain relatively preliminary data 
and several factors could account for these appar-
ently negative results. Most obviously perhaps is the 
fact that there may be some degree of differential 
loss of the two compounds in the culture medium 
over  the  time  course  of  this  work.  3-hydroxyan-
thranilic acid, for example, is much less stable than 
anthranilic  acid  in  aqueous  solution  (see  below), 
with  auto-oxidation  producing  a  rapid  loss  of  3-
hydroxyanthranilic acid compared with anthranilic 
acid.21,22 It would be of interest to assess the levels of 
both compounds at different stages of the cell culture 
experiments to address this question, and to ensure a 
frequent replenishment of the 3-hydroxyanthranilic 
acid so as to maintain a consistent balance with the 
level of anthranilic acid.
Biological importance  
of 3-hydroxyanthranilic acid:  
anthranilic acid ratio
The  existence  of  such  marked  changes  in  3-
hydroxyanthranilic acid and anthranilic acid in a range 
of clinical disorders suggests a possible relevance to 
the disease process or recovery, especially since the 
changes were almost invariably reciprocal, with low 
3-hydroxyanthranilic acid levels and raised AA levels. 
This degree of reciprocity suggests a consistent bio-
chemical change, rather than purely random changes 
in the levels of one or other of these compounds.
There  are  two  possible  reasons  why  3-
hydroxyanthranilic acid in particular might be rel-
evant to the disease process. Firstly, it is a highly 
reactive  compound,  which  readily  auto-oxidises  to 
a dimeric analogue, cinnabarinic acid.21,22 The auto-
oxidation process has been studied in some detail by 
Dykens et al21 and Iwahashi et al23 who have noted 
the  ability  of  ambient  redox  conditions  to  affect 
the rate of transformation, especially in the face of 
changed levels of superoxide dismutase activity. It is 
probably the ability of 3-hydroxyanthranilic acid to 
modify the local redox environment which accounts 
for its toxic effects on some cell types.20 Whether 3-
hydroxyanthranilic acid is pro- or anti-oxidant24 in 
any one situation will depend, as for any other com-
pound, on the local redox conditions.
Secondly, 3-hydroxyanthranilic acid and anthra-
nilic  acid  are  known  to  interact  at  the  level  of 
3-hydroxyanthranilic  acid  oxidase  (3HAO).  This 
enzyme  is  known  to  exist  in  central  neurons  and 
anthranilic acid is an effective inhibitor, reducing the 
conversion  of  3-hydroxyanthranilic  acid  to  quino-
linic acid and picolinic acid.25 Using a concentration 
of  300  µM  3-hydroxyanthranilic  acid  as  substrate 
for 3HAO, anthranilic acid is a competitive inhibitor 
with a Ki of 40 µM.26 The ratio of 300 µM substrate 
to 40 µM inhibitor Ki indicates that anthranilic acid 
is highly effective as an inhibitor at around 13% of 
the natural substrate. At the ratio seen in blood sam-
ples, therefore, in which anthranilic acid concentra-
tions normally equal or exceed 3-hydroxyanthranilic 
acid levels by up to 5-fold (Table 1), there should 
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Figure 1. Neurotoxic  effects  of  3-hydroxyanthranilic  acid/anthranilic 
acid combinations. The effects on neuronal viability (cerebellar granule 
neurons) of different ratios of AA and 3-hydroxyanthranilic acid. In these 
selected examples of a wider series, 3-hydroxyanthranilic acid (3HAA) 
at a concentration of 100 µM is illustrated in combination with anthranilic 
acid (AA) at concentrations ranging from 0 to 1000 µM. Although there is a 
clear trend for the higher concentration to increase 3-hydroxyanthranilic 
acid—induced  neurotoxicity,  lower  concentrations  tend  to  reduce  the 
damage, although none reached statistical significance in this series. 
Although the range of concentrations illustrated showed no significant 
interaction, lower concentrations which were closer to those measured 
in human blood, also showed no apparent interaction in this system. No 
clear, significant interactions were seen when the ratios of 3HAA:AA were 
reversed. The number of experiments is indicated within each column. 
(Adapted from A J smith, phD thesis, University of Glasgow, 2008).Darlington et al
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be substantial overall inhibition of the enzyme. It is 
likely that the enzyme status in vivo will be deter-
mined by a plethora of factors and co-factors which 
make  this  conclusion  more  or  less  correct,  but  it 
remains probable that in normal humans the conver-
sion of 3-hydroxyanthranilic acid to quinolinate will 
be limited by endogenous levels of anthranilate.
It is interesting to speculate, therefore, that in the 
patient groups, in whom the ratio of 3HAA:AA is 
invariably less than in control subjects (Table 1), this 
limitation of quinolinic acid formation may reflect a 
compensatory mechanism to reduce cell toxicity.
The immune system
Thirdly, changes in the levels of 3-hydroxyanthranilic 
acid are increasingly recognised as being highly active 
in modulating the activity of T cells in the immune 
system. It has the ability to depress the release of 
cytokines  from  both  T  helper-1  (Th1)  cells  and 
Th2 cells, although in early or mild cases of inflam-
mation the major effect seems to be on Th1, whereas 
more advanced, chronic inflammation is usually asso-
ciated with a preferential action on Th2 cells.27,28 In 
addition, 3-hydroxyanthranilic acid can have a direct 
anti-proliferative effect on Th1 and Th2 cells under 
the  same—acute  or  chronic—inflammatory  condi-
tions.28–30  At  the  molecular  level  it  has  also  been 
demonstrated  that  3-hydroxyanthranilic  acid  can 
suppress the activation of the pro-inflammatory tran-
scription factor Nuclear Factor kappa-B (NFκB),28,31 
as well as inhibiting nitric oxide synthase.31,32 There 
is also a highly specific ability to inhibit the stimu-
lation  of T  cell  activity  by  dendritic  cells.33,34 The 
secretion  of  monocyte  chemoattractant  protein-1 
(MCP-1) is depressed by 3-hydroxyanthranilic acid, 
an effect probably mediated via the induction of haem 
oxygenase-1.35 Changing levels of 3-hydroxyanthra-
nilic acid could, therefore, exert a profound effect on 
the overall activity of T cells and the balance of Th1 
and Th2 cell activity.33,34
Mechanisms of changing levels
At present there is no clear indication of the biochem-
ical mechanism which leads to the change in levels 
of  3-hydroxyanthranilic  acid  and  anthranilic  acid. 
Baran and Schwarcz36 were able to demonstrate that, 
when added to brain homogenates, anthranilic acid 
could  be  readily  converted  into  3-hydroxyanthra-
nilic acid, a transformation which they attributed to 
a hypothetical anthranilate oxidase activity. In prin-
ciple, a loss of such activity would lead to the fall in 
3-hydroxyanthranilic acid levels and the accumula-
tion of anthranilic acid.
In addition, the ability of anthranilic acid to inhibit 
3HAO as discussed above, means that any change in 
the level of the former will have a direct influence 
not only as described in the previous paragraph, on 
3-hydroxyanthranilic acid levels but also on the pro-
duction of quinolinic acid from 3-hydroxyanthranilic 
acid,  with  secondary  effects  on  nicotinic  acid  and 
NAD levels as well as the potential for quinolinic 
acid to produce activation and excitotoxicity of neu-
rones in the central and peripheral systems.
It is possible that the levels and availability of iron 
may also play a substantial role in determining both the 
absolute and relative levels of 3-hydroxyanthranilic 
acid and anthranilic acid. Several metal ions known 
to inhibit 3HAO, iron (Fe3+) being one of the most 
potent. This ion produces a non-competitive inhibi-
tion with a Km for iron of 6.3 µM. It is relevant then 
that  anthranilic  acid  is  able  to  chelate  metal  ions, 
especially Fe3+, and is able to promote the reduc-
tion of Fe3+ to Fe2+ in aqueous solution.37 This may 
also be relevant to the cell culture results described 
earlier, since the higher concentrations of anthranilic 
acid may have chelated a significant fraction of the 
iron required for neuronal survival in vitro. Indeed, 
the high levels of anthranilic acid generated by the 
inhibition  of  kynurenine-3-monoxygenase  in  an  in 
vivo model of cerebral malaria38 could have chelated 
enough circulating iron to contribute to the anaemia 
reported in that study. Similar metal interactions have 
been proposed as having important physiological rel-
evance in the mechanism of transmembrane transport 
of those ions39 so that a range of metabolic conse-
quences might result from a general disturbance of 
metal ion absorption or availability to the intracellu-
lar milieu.
Another—not  necessarily  contradictory—hypoth-
esis  might  be  based  around  the  role  of  riboflavin 
(vitamin B2) as a co-factor for the enzyme kynurenine-
3-monoxygenase (KMO).40,41 There is an existing lit-
erature on the fact that infection or inflammation is 
associated with a marked loss of intracellular stores 
of riboflavin.42 Indeed, an abundant supply of intracel-
lular riboflavin is required for effective resistance to 3-hydroxyanthranilic acid
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infection,43 with riboflavin depletion affording a loss 
of that resistance44 It is, therefore, tempting to hypothe-
sise that the onset of infection or inflammation is associ-
ated with a loss of intracellular riboflavin, which results 
in a decreased activity of KMO. This would reduce the 
conversion of kynurenine to 3-hydroxykynurenine (and 
thus to 3-hydroxyanthranilic acid), and drive kynurenine 
along the accepted alternative route to anthranilic acid 
(Fig. 2).
This  proposal  is  entirely  consistent  with  exist-
ing experimental data, since it has been shown that 
the  administration  of  a  compound  which  inhibits 
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Figure 2. Key elements of the kynurenine pathway.Darlington et al
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KMO (Ro61-8048), does generate a massive 40-fold 
increase of brain anthranilic acid levels (from 2.0 ± 
0.3 to 76.9 ± 23.3 fmols/mg protein), which is in turn 
increased a further 6-fold (to 487.0 ± 96 fmols/mg 
protein) in animals infected with malaria parasites.38
Implications for therapy
If this hypothesis is correct, then the administration 
of riboflavin might correct the cellular loss of KMO 
activity, restoring 3-hydroxyanthranilic acid levels to 
normal, correcting any induced changes in T cell func-
tion, and reducing overall levels of inflammation.
Of course, the changed 3-hydroxyanthranilic acid:
anthranilic acid ratio may simply be an epiphenome-
non, reflecting other, more important cellular changes 
which occur as a result of riboflavin depletion but 
without being critical to the overall degree of inflam-
matory  activity.  However,  the  therapeutic  implica-
tion may still be correct, that riboflavin could be an 
effective corrective therapy, or adjunctive therapy, for 
some inflammatory disorders whatever the primary 
cellular machinery which is involved.
summary
We present data to show that in a wide range of clinical 
diseases—chronic brain injury, Huntington’s disease, 
stroke, depression, coronary heart disease, intratho-
racic  disease  including  neoplasia  and  osteoporosis 
the normal ratio between 3-hydroxyanthranilic acid 
and anthranilic acid is changed, with lower levels of 
3-hydroxyanthranilic acid and higher levels of anthra-
nilic acid than normal.
The exact reasons for this reversed ratio are uncer-
tain but a decreased 3HAA:AA ratio should produce a 
‘cleaning up’ effect after insult or injury, antagonism 
of  quinolinic  acid  toxicity,  reduction  in  oxidative 
stress, protection against immunostimulation, immu-
nosuppression and a reduced inflammatory response. 
All of these actions could protect against primary and 
secondary damage after an insult, and would be espe-
cially relevant in the brain.
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